nmadmin

We are very happy to today announce the foundation of VarCT Diagnostics ApS, a sister company to VAR2 Pharmaceuticals. VarCT Diagnostics will, based on our proprietary malaria protein, focus on the development of a universal tool to capture circulating tumour cells (CTC) as means for diagnosis, prognosis and monitoring of cancer during treatment. The transfer of the […]

It is with great pleasure that VAR2 Pharmaceuticals can announce that our first patent has been issued by the Australian Government (IP Australia). Key claims on the use of recombinant VAR2CSA for targeting, treating and diagnosing cancer was accepted and issued.

Cisplatin is worldwide standard-of-care chemotherapy in muscle-invasive bladder cancer (MIBC). However, many patients develop resistance to cisplatin with no second-line treatment options currently available. A new study published on April 10, 2017 in European Urology demonstrates VAR2-mediated drug delivery as a putative second-line treatment strategy in cisplatin-resistant MIBC. Bladder cancer is the 5th most common […]

VAR2Pharmaceuticals will be present at PEGS conference in Boston May 1-5. To arrange a meeting please contact salanti@var2pharmaceuticals.com

The role of oncofetal CSA is published in a major article in ”Molecular Cancer Research” by the founders of VAR2Pharmaceuticals. The publication was choosen as the front cover of the monthly peer reviewed journal and describes that onco-fetal CSA plays a key role in metastasis formation and that treatment of animals with recombinant VAR2CSA hinders […]

VAR2Pharmaceuticals announces the finalization of the second investment round of 3.3M Euros. ”We are very pleased to have secured further funding for our exciting portfolie of pre-clinical development programs” says CEO Ali Salanti.

VAR2Pharmaceuticals receives a 7 million DKK grant from the Danish Innovation Foundation for ”Targeting cancer using a malaria derived protein drug conjugate”.

Copenhagen, Denmark, October 13, 2015:   Targeting carbohydrates provides a new Danish biotech company, VAR2 Pharmaceuticals, with an effective weapon against cancer. Today VAR2 Pharmaceuticals announced the publication of breakthrough data in the renowned scientific journal Cancer Cell. The young Danish biotech company VAR2 Pharmaceuticals faces a possible breakthrough in the fight against cancer, which may result […]

VAR2 Pharmaceuticals has received an extended Knowledge Voucher from Danish Council for Technology and Innovation. The Voucher will be used to establish a collaboration between researchers at University of Copenhagen and Bioneer with the aim at optimizing production methods and stability of our proprietary cancer targeting molecules prior to GMP production for the first human […]